Scholarlink

<p>Associations between holistic oncologic management (HOM) and the trajectory of quality of life (QoL) in patients with non-small cell lung cancer (NSCLC) have not been evaluated, especially the driver-gene-negative NSCLC patients, whose QoL was proved to be poorer. This randomized controlled trial is performed from October 23, 2019, to July 25, 2023. Patients diagnosed with driver-gene-negative NSCLC were enrolled in Chongqing University Cancer Hospital and were classified into 2 groups: the control arm (arm C) and the treatment arm (arm T). The holistic integrative oncologic therapy was strictly implemented in the arm T, focusing on four basic elements: QoL, depression, pain and nutrition. Patients were comprehensively intervened and assessed in 24 consecutive weeks (i.e. four weeks/cycle, six cycles in total). Six-point QoL trajectories were derived from latent growth curve modeling (LGCM) analyses. The QoL was evaluated by the Functional Assessment of Cancer Therapy–Lung (FACT-L). Participants in two groups were 81 and 77, respectively. The HOM was shown to significantly enhance the QoL, alleviate cancer-related pain, and improve nutritional status and mood symptoms in driver-gene-negative NSCLC patients. Notably, younger patients have experienced more significant improvements. HOM improves the QoL in patients with driver-gene-negative advanced NSCLC, especially in patients with younger age. Trial Registration The research was retrospectively registered on 11/11/2024, in the Chinese Clinical Trial Registry (<a href="http://www.chictr.org.cn/ChiCTR2400092132">http://www.chictr.org.cn/ChiCTR2400092132</a>).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Holistic oncologic management improves quality of life in driver gene negative advanced NSCLC a latent growth curve modeling study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月12日

查看全文
  • Li-Ling Ma,
  • Jun-Hui Zhang,
  • Lei Lei,
  • Xia Lei,
  • Shi-Hong Liu,
  • Xin Zhang,
  • Hong Yang,
  • Lie-Jun Yang,
  • Ling Tian,
  • Si-Xiong Wang,
  • Ya-Fei Li,
  • Hui-Qing Yu

摘要

Associations between holistic oncologic management (HOM) and the trajectory of quality of life (QoL) in patients with non-small cell lung cancer (NSCLC) have not been evaluated, especially the driver-gene-negative NSCLC patients, whose QoL was proved to be poorer. This randomized controlled trial is performed from October 23, 2019, to July 25, 2023. Patients diagnosed with driver-gene-negative NSCLC were enrolled in Chongqing University Cancer Hospital and were classified into 2 groups: the control arm (arm C) and the treatment arm (arm T). The holistic integrative oncologic therapy was strictly implemented in the arm T, focusing on four basic elements: QoL, depression, pain and nutrition. Patients were comprehensively intervened and assessed in 24 consecutive weeks (i.e. four weeks/cycle, six cycles in total). Six-point QoL trajectories were derived from latent growth curve modeling (LGCM) analyses. The QoL was evaluated by the Functional Assessment of Cancer Therapy–Lung (FACT-L). Participants in two groups were 81 and 77, respectively. The HOM was shown to significantly enhance the QoL, alleviate cancer-related pain, and improve nutritional status and mood symptoms in driver-gene-negative NSCLC patients. Notably, younger patients have experienced more significant improvements. HOM improves the QoL in patients with driver-gene-negative advanced NSCLC, especially in patients with younger age. Trial Registration The research was retrospectively registered on 11/11/2024, in the Chinese Clinical Trial Registry (http://www.chictr.org.cn/ChiCTR2400092132).